Michael Altaweel, MD
Enriched profileProfessor, Department of Ophthalmology and Visual Sciences; Retina Service Chief; Vitreoretinal Surgery Fellowship Director · University of Wisconsin-Madison School of Medicine and Public Health
Michael Altaweel is Professor, Department of Ophthalmology and Visual Sciences; Retina Service Chief; Vitreoretinal Surgery Fellowship Director at University of Wisconsin-Madison School of Medicine and Public Health. OpenAlex indexes 117 publications with 4,776 citations (h-index 29); ClinicalTrials.gov lists 4 registered studies with this person as an investigator.
Data verified 9 Oct 2026
Overview
Updated 14 Oct 2026
Michael Altaweel, MD, is Professor, Department of Ophthalmology and Visual Sciences at University of Wisconsin-Madison School of Medicine and Public Health. The public record shows 117 publications with 4,776 citations (h-index 29), centered on Retinal Diseases and Treatments, Ocular Diseases and Behçet’s Syndrome, Retinal and Macular Surgery. It also documents an investigator role on 4 registered clinical trials, industry payments reported by 2 companies, 3 NIH-funded awards (2004–2022).
- Most recent indexed publication: 2024 · Journal of clinical oncology
- Top research focus: Retinal Diseases and Treatments
- 4 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 2 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 46.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 4 registered studies on ClinicalTrials.gov. The most recent:
- Lamivudine and Plasma Markers of Inflammation in Retinal Detachment
Sponsor: University of Wisconsin, Madison
- Bevacizumab Against Recurrent Retinal Detachment
Sponsor: University of Wisconsin, Madison
- Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects
Sponsor: University of Wisconsin, Madison
Industry payments
Updated 14 Oct 2026
2 companies reported payments to CMS in program years 2023–2025. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20251 payment
- Apellis Pharmaceuticals, Inc.Program year20231 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
80.6%Corticosteroid21.8%Prednisolone Acetate100%Part D≥43 patientsCarbonic Anhydrase Inhibitor18%Dorzolamide-Timolol57%Dorzolamide Hcl43%Part D<11 patients+ 4 more classes in this area
Musculoskeletal
14.5%Cyclooxygenase Inhibitor14.5%Ketorolac Tromethamine100%Part D≥18 patientsCardiovascular
4.8%Beta blocker4.8%Timolol Maleate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
3 NIH research awards on record, funded 2004–2022 per NIH RePORTER. The latest:
- Researching OCT Biomarkers in UveitiS clinical Trials (ROBUST)
University of California Los Angeles
FY2026$722,904R01EY037916 - ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial
University of Wisconsin-Madison
FY2022$282,710UG1EY028087 - ADalimimab Vs conventional ImmunoSupprEssion for uveitis (ADVISE) Trial
University of Wisconsin-Madison
FY2021$282,710UG1EY028087
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophth.wisc.edu ↗
Awards & honors
honors on the public record- Monroe E. Trout Chair in Eye Research
McPherson Eye Research Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophth.wisc.edu ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Wisconsin Reading Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophth.wisc.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ophth.wisc.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Richard Spaide, MD
Vitreous Retina Macula Consultants of New York